Birchview Capital LP cut its position in Quotient Limited (NASDAQ:QTNT) by 25.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,700 shares of the company’s stock after selling 20,000 shares during the quarter. Quotient Limited makes up approximately 0.2% of Birchview Capital LP’s investment portfolio, making the stock its 29th largest holding. Birchview Capital LP owned about 0.16% of Quotient Limited worth $294,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in QTNT. New York State Common Retirement Fund bought a new position in Quotient Limited in the second quarter worth about $101,000. Goldman Sachs Group Inc. bought a new position in Quotient Limited in the second quarter worth about $104,000. Nationwide Fund Advisors bought a new position in Quotient Limited in the second quarter worth about $111,000. The Manufacturers Life Insurance Company bought a new position in Quotient Limited in the second quarter worth about $177,000. Finally, Rhumbline Advisers bought a new position in Quotient Limited in the second quarter worth about $201,000. Institutional investors and hedge funds own 47.70% of the company’s stock.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Quotient Limited from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. BTIG Research reiterated a “buy” rating and issued a $12.00 target price on shares of Quotient Limited in a report on Wednesday, November 1st. Jefferies Group LLC reduced their target price on shares of Quotient Limited from $15.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, November 1st. Finally, ValuEngine downgraded shares of Quotient Limited from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/08/birchview-capital-lp-sells-20000-shares-of-quotient-limited-qtnt.html.

In other news, insider D J. Paul E. Cowan sold 45,540 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $3.52, for a total transaction of $160,300.80. Following the sale, the insider now owns 26,666 shares in the company, valued at $93,864.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider D J. Paul E. Cowan sold 30,197 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $4.92, for a total value of $148,569.24. Following the sale, the insider now owns 26,666 shares in the company, valued at approximately $131,196.72. The disclosure for this sale can be found here. Insiders sold 375,197 shares of company stock valued at $1,639,728 over the last quarter. 29.00% of the stock is currently owned by corporate insiders.

Shares of Quotient Limited (NASDAQ QTNT) traded down $0.04 during mid-day trading on Wednesday, hitting $4.72. The stock had a trading volume of 137,120 shares, compared to its average volume of 335,785. The company has a debt-to-equity ratio of -5.17, a quick ratio of 0.86 and a current ratio of 1.36. Quotient Limited has a 1-year low of $3.22 and a 1-year high of $7.74.

Quotient Limited (NASDAQ:QTNT) last announced its earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.55). The business had revenue of $6.83 million during the quarter, compared to the consensus estimate of $5.70 million. Quotient Limited had a negative net margin of 404.29% and a negative return on equity of 13,050.41%. sell-side analysts predict that Quotient Limited will post -2.1 EPS for the current year.

Quotient Limited Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Limited (NASDAQ:QTNT).

Institutional Ownership by Quarter for Quotient Limited (NASDAQ:QTNT)

Receive News & Stock Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related stocks with our FREE daily email newsletter.